Can a 'Clean-Up' drug make chemo safer for brain lymphoma?
NCT ID NCT03684980
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests whether adding glucarpidase (Voraxaze) to standard methotrexate and rituximab can safely lower methotrexate levels in the blood for people with central nervous system lymphoma. About 58 participants will receive different doses of methotrexate along with glucarpidase to see how well it reduces drug levels and side effects. The goal is to make the standard treatment safer, not to cure the disease at this stage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Glucarpidase (also called Voraxaze)
What this could lead to
If it works, this could make standard chemotherapy safer by quickly clearing methotrexate from the blood, reducing toxic side effects.
What could go wrong
This is a very early, small pilot study (58 people) focused on safety and drug levels, not on curing the disease. It may not lead to better outcomes or be confirmed in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Cleveland Clinic (Data Collection and Specimen Collection)
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute (Data Collection and Specimen Analysis)
Boston, Massachusetts, 02115, United States
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States